Company Profile

Resonance Health (RHT) is an Australian Healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI) related technology.

Our lead product is FerriScan, a world leading non-invasive tool for measuring liver iron levels. FerriScan is the first non-invasive test for liver iron concentration to have achieved regulatory clearances in the US, Europe and Australia.

The FerriScan service involves an MRI scan followed by off-site processing of the images by Resonance Health using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the Resonance Health analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level.

FerriScan provides a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

Resonance Health is also developing a new non-invasive test for the measurement of liver fibrosis. With the World Health Organisation (WHO) estimating more than 170 million people worldwide are affected by Hepatitis C, a major cause of liver fibrosis, there is a massive unmet clinical need for a new non-invasive and accurate test that quantifies fibrosis.